2 Pharmaceutical Stocks Set to Rebound in 2026
The healthcare sector lagged broader equities last year. Novo Nordisk (NYSE: NVO) and (NYSE: MRK), two pharmaceutical leaders, were among the underperformers. But here's the good news: There are solid reasons to think the two leading drugmakers will do much better this year. Here is why Novo Nordisk and Merck could rebound in 2026.
Last year, Novo Nordisk lost market share to its biggest competitor in the all-important weight management drug market. The company also experienced some clinical setbacks. However, the Denmark-based drugmaker could perform much better in 2026. First, Novo Nordisk has earned important label expansions for some of its products. Wegovy is now approved for patients with metabolic dysfunction-associated steatohepatitis.
Image source: Getty Images.
Source Fool.com
Merck KGaA Aktie
Merck KGaA wird von der Community leicht favorisiert: Mehr Buy- als Sell-Einschätzungen.
Ein positives, wenn auch bescheidenes, Potenzial für Merck KGaA mit einem Kursziel von 135 € im Vergleich zum aktuellen Kurs von 125.4 €.
